Diabetes, Vol 43, Issue 3 447-453, Copyright © 1994 by American Diabetes Association

ARTICLES

Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts

M Kellerer, G Kroder, S Tippmer, L Berti, R Kiehn, L Mosthaf and H Haring
Institute for Diabetes Research, Munich, Germany.

Troglitazone (CS045), a compound belonging to the thiazolidine diones, is being tested as a new oral antidiabetic agent. Evidence exists from animal studies and clinical trials with non-insulin-dependent diabetes mellitus patients that Troglitazone might reduce insulin resistance. The molecular mechanism of this effect is not understood. In this study, we investigated whether Troglitazone might interfere with the mechanism of glucose-induced insulin resistance. Several studies indicate that hyperglycemia reduces the kinase activity of the insulin receptor in different cell types. This effect is paralleled by translocation of several protein kinase C (PKC) isoforms, and it can be prevented by PKC inhibitors, which suggests that glucose-induced receptor desensitization is mediated by activation of PKC. We studied the effect of hyperglycemia on the insulin receptor kinase activity and its modulation by Troglitazone in rat-1 fibroblasts that stably overexpress the human insulin receptor. Before stimulation with insulin (10(-7) M), cells were acutely exposed to hyperglycemic conditions in the absence or presence of Troglitazone (0.01-2 micrograms/ml). The insulin receptor was solubilized from a plasma membrane fraction or whole cell lysates, and proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblotted against antiphosphotyrosine and anti-insulin receptor beta-subunit (CT 104) antibodies. Acute hyperglycemia (25 mM glucose) induced a significant inhibition of the insulin receptor kinase (IRK) activity within 30 min (inhibition to 30 +/- 12.5% of maximal insulin-stimulated beta-subunit phosphorylation, n = 9, P < 0.01).(ABSTRACT TRUNCATED AT 250 WORDS)
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				Y.-B. Kim, T. P. Ciaraldi, A. Kong, D. Kim, N. Chu, P. Mohideen, S. Mudaliar, R. R. Henry, and B. B. Kahn Troglitazone but not Metformin Restores Insulin-Stimulated Phosphoinositide 3-Kinase Activity and Increases p110{beta} Protein Levels in Skeletal Muscle of Type 2 Diabetic Subjects Diabetes, February 1, 2002; 51(2): 443 - 448. [Abstract] [Full Text] [PDF]

				I. Gabriely, R. Wozniak, M. Hawkins, and H. Shamoon Troglitazone Amplifies Counterregulatory Responses to Hypoglycemia in Nondiabetic Subjects J. Clin. Endocrinol. Metab., February 1, 2001; 86(2): 521 - 528. [Abstract] [Full Text]

				H. E. Lebovitz, J. F. Dole, R. Patwardhan, E. B. Rappaport, and M. I. Freed Rosiglitazone Monotherapy Is Effective in Patients with Type 2 Diabetes J. Clin. Endocrinol. Metab., January 1, 2001; 86(1): 280 - 288. [Abstract] [Full Text]

				S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring Pathophysiology and Pharmacological Treatment of Insulin Resistance Endocr. Rev., December 1, 2000; 21(6): 585 - 618. [Abstract] [Full Text]

				K. Yasunari, M. Kohno, H. Kano, K. Yokokawa, M. Minami, and J. Yoshikawa Antioxidants Improve Impaired Insulin-Mediated Glucose Uptake and Prevent Migration and Proliferation of Cultured Rabbit Coronary Smooth Muscle Cells Induced by High Glucose Circulation, March 16, 1999; 99(10): 1370 - 1378. [Abstract] [Full Text] [PDF]

				J. Kawasaki, K. Hirano, J. Nishimura, M. Fujishima, and H. Kanaide Mechanisms of Vasorelaxation Induced by Troglitazone, a Novel Antidiabetic Drug, in the Porcine Coronary Artery Circulation, December 1, 1998; 98(22): 2446 - 2452. [Abstract] [Full Text] [PDF]

				L. S. Liu, H. Tanaka, S. Ishii, and J. Eckel The New Antidiabetic Drug MCC-555 Acutely Sensitizes Insulin Signaling in Isolated Cardiomyocytes Endocrinology, November 1, 1998; 139(11): 4531 - 4539. [Abstract] [Full Text] [PDF]

				K. S. Park, T. P. Ciaraldi, K. Lindgren, L. Abrams-Carter, S. Mudaliar, S. E. Nikoulina, S. R. Tufari, J. H. Veerkamp, A. Vidal-Puig, and R. R. Henry Troglitazone Effects on Gene Expression in Human Skeletal Muscle of Type II Diabetes Involve Up-Regulation of Peroxisome Proliferator-Activated Receptor-{gamma} J. Clin. Endocrinol. Metab., August 1, 1998; 83(8): 2830 - 2835. [Abstract] [Full Text]

				K. S. Park, T. P. Ciaraldi, L. Abrams-Carter, S. Mudaliar, S. E. Nikoulina, and R. R. Henry Troglitazone Regulation of Glucose Metabolism in Human Skeletal Muscle Cultures from Obese Type II Diabetic Subjects J. Clin. Endocrinol. Metab., May 1, 1998; 83(5): 1636 - 1643. [Abstract] [Full Text]

				K.-I. Ohtani, H. Shimizu, N. Sato, and M. Mori Troglitazone (CS-045) Inhibits {beta}-Cell Proliferation Rate Following Stimulation of Insulin Secretion in HIT-T 15 Cells Endocrinology, January 1, 1998; 139(1): 172 - 178. [Abstract] [Full Text] [PDF]

				J. E-B. Reusch Focus on Insulin Resistance in Type 2 Diabetes: Therapeutic Implications The Diabetes Educator, January 1, 1998; 24(2): 188 - 193. [PDF]

				K. Yasunari, M. Kohno, H. Kano, K. Yokokawa, M. Minami, and J. Yoshikawa Mechanisms of Action of Troglitazone in the Prevention of High Glucose-Induced Migration and Proliferation of Cultured Coronary Smooth Muscle Cells Circ. Res., December 19, 1997; 81(6): 953 - 962. [Abstract] [Full Text]

				K. Izumino, H. Sakamaki, M. Ishibashi, H. Takino, H. Yamasaki, Y. Yamaguchi, N. Chikuba, K. Matsumoto, S. Akazawa, K. Tokuyama, et al. Troglitazone Ameliorates Insulin Resistance in Patients with Werner's Syndrome J. Clin. Endocrinol. Metab., August 1, 1997; 82(8): 2391 - 2395. [Abstract] [Full Text] [PDF]

				H. Maegawa, R. Ide, M. Hasegawa, S. Ugi, K. Egawa, M. Iwanishi, R. Kikkawa, Y. Shigeta, and A. Kashiwagi Thiazolidine Derivatives Ameliorate High Glucose-induced Insulin Resistance via the Normalization of Protein-tyrosine Phosphatase Activities J. Biol. Chem., March 31, 1995; 270(13): 7724 - 7730. [Abstract] [Full Text] [PDF]